Optimizing Cigna Kesimpta Prior Authorization Workflows

Navigating Kesimpta Prior Authorization with Cigna Healthcare

Kesimpta, a CD20-directed cytolytic antibody for relapsing forms of multiple sclerosis (RMS), often requires prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans under Cigna Healthcare. The specific pathway for submission depends on whether the drug is covered under the medical or pharmacy benefit, influencing which Cigna entity manages the review.

Key Submission Channels for Kesimpta with Cigna Healthcare

• **Medical Benefit PA:** For Kesimpta administered under the medical benefit, submissions are primarily routed through CignaforHCP.com, Cigna Healthcare's provider portal. X12 278 transactions are also accepted via clearinghouses for electronic submission.
• **Pharmacy Benefit PA:** When Kesimpta is covered under the pharmacy benefit, prior authorizations are managed by Express Scripts, the PBM operating under the Evernorth health services brand.
• **ePA Solutions:** Express Scripts supports electronic prior authorization (ePA) for pharmacy benefit submissions through established partners like CoverMyMeds and Surescripts, facilitating prescriber-initiated workflows.
• **Specialty Pharmacy:** Accredo, the specialty pharmacy under Express Scripts and Evernorth, handles specialty injectable and complex medication PAs on the pharmacy benefit, including many high-cost therapies like Kesimpta.

Cigna Healthcare's Coverage Policies and Criteria for Kesimpta

Cigna Healthcare publishes specific coverage policies and medical-necessity guidelines that govern Kesimpta approvals. These policies, accessible through the public provider site, are versioned and dated, often referencing criteria developed by Cigna, or based on external sources like MCG or NCCN compendia, particularly for oncology drugs. Understanding the clinical indications and any step therapy requirements outlined in these policies is vital for a successful submission.

Electronic Prior Authorization (ePA) Posture for Kesimpta under Evernorth

Evernorth, through Express Scripts, maintains robust electronic prior authorization capabilities for pharmacy benefits, leveraging integrations with CoverMyMeds and Surescripts. Cigna Healthcare also participates in the HL7 Da Vinci Project ecosystem, indicating a commitment to advancing electronic data exchange for prior authorization, including potential for future SMART on FHIR-enabled workflows.

Common Denial Reasons for Kesimpta Prior Authorization with Cigna Healthcare

• **Medical Necessity:** Insufficient clinical documentation to support the medical necessity criteria outlined in Cigna Healthcare's policies.
• **Step Therapy Requirements:** Failure to demonstrate adherence to required preceding therapies or a documented contraindication to those therapies.
• **Insufficient Documentation:** Missing or incomplete patient records, lab results, or physician notes required for review.
• **Non-Formulary or Quantity Limits:** Issues related to the Express Scripts formulary, preferred drug lists, or exceeding approved quantity limits.
• **Site-of-Service Mismatch:** Discrepancies between the proposed site of care and Cigna Healthcare's site-of-service guidelines for infusion or administration.

Expediting Kesimpta Prior Authorization Appeals with Cigna Healthcare

In the event of a denial, Cigna Healthcare provides structured appeal pathways, detailed on the provider portal and in the Cigna Provider Manual. Peer-to-peer reviews are available for clinical denials, allowing a direct discussion with a Cigna medical director. Expedited appeals are also an option for urgent care needs, with distinct processes for commercial versus Medicare Advantage lines.

Klivira's Role in Streamlining Cigna Kesimpta Prior Authorizations

Klivira's platform automates the complex process of **Cigna Kesimpta prior authorization**, integrating directly with EMRs and payer portals like CignaforHCP. By leveraging intelligent automation and real-time connectivity, Klivira helps clinics, hospitals, and health systems accelerate PA submissions, minimize manual effort, and proactively address Cigna Healthcare's specific requirements, reducing turnaround times and improving approval rates for critical specialty medications.